{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T15:39:03Z","timestamp":1782229143344,"version":"3.54.5"},"reference-count":5,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2003,10,1]],"date-time":"2003-10-01T00:00:00Z","timestamp":1064966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"vor","delay-in-days":4444,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Investigative Dermatology Symposium Proceedings"],"published-print":{"date-parts":[[2003,10]]},"DOI":"10.1046\/j.1087-0024.2003.00813.x","type":"journal-article","created":{"date-parts":[[2003,9,22]],"date-time":"2003-09-22T12:49:39Z","timestamp":1064234979000},"page":"217-218","source":"Crossref","is-referenced-by-count":9,"title":["The New Biologics in Psoriasis: Possible Treatments for Alopecia Areata"],"prefix":"10.1016","volume":"8","author":[{"given":"Amy J.","family":"McMichael","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1046\/j.1087-0024.2003.00813.x_bb0010","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0167-5699(98)01381-4","article-title":"The pathogenesis of psoriasis: Immunologic facts and speculations","volume":"20","author":"Bos","year":"1999","journal-title":"Immunol Today"},{"key":"10.1046\/j.1087-0024.2003.00813.x_bb0015","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","article-title":"Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomised trial","volume":"357","author":"Chaudhari","year":"2001","journal-title":"Lancet"},{"key":"10.1046\/j.1087-0024.2003.00813.x_bb0020","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1001\/archderm.138.5.591","article-title":"Psoriasis as a model for T-cell-mediated disease. Immunologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody","volume":"138","author":"Gottlieb","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1046\/j.1087-0024.2003.00813.x_bb0025","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/archderm.135.9.1104","article-title":"The immunologic basis of psoriasis","volume":"135","author":"Nickoloff","year":"1999","journal-title":"Arch Dermatol"},{"key":"10.1046\/j.1087-0024.2003.00813.x_bb0030","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/archderm.138.5.657","article-title":"Biologic therapy for psoriasis: The new therapeutic frontier","volume":"138","author":"Singri","year":"2002","journal-title":"Arch Dermatol"}],"container-title":["Journal of Investigative Dermatology Symposium Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X15529709?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X15529709?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,23]],"date-time":"2019-02-23T19:56:59Z","timestamp":1550951819000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X15529709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,10]]},"references-count":5,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003,10]]}},"alternative-id":["S0022202X15529709"],"URL":"https:\/\/doi.org\/10.1046\/j.1087-0024.2003.00813.x","relation":{},"ISSN":["1087-0024"],"issn-type":[{"value":"1087-0024","type":"print"}],"subject":[],"published":{"date-parts":[[2003,10]]}}}